Literature DB >> 20719041

Does executive impairment define a frontal variant of Alzheimer's disease?

Michael Woodward1, Henry Brodaty, Karyn Boundy, David Ames, Greg Blanch, Robert Balshaw.   

Abstract

BACKGROUND: People with Alzheimer's disease (AD) who present with prominent frontal features such as a dysexecutive syndrome may be difficult to differentiate clinically from subjects with frontotemporal lobar degeneration (FTLD). This study was performed to improve the differential diagnosis between AD and FTLD and to better characterize the AD subgroup with greater executive dysfunction.
METHODS: Using a well-defined prospectively studied cohort of cognitively impaired subjects, which included those with AD and with FTLD, we nominated a frontal variant of AD (FvAD) group as those AD subjects with the lowest quartile of scores on the Frontal Assessment Battery (FAB), indicating greatest executive dysfunction, and compared them with the rest of the AD cases (whom we called the AD group) and those with FTLD across several baseline variables including cognitive, functional and behavioral scales. We also compared the changes from baseline for these three groups at 6 and 12 months. Additionally, we controlled for dementia severity by matching AD and FTLD cases on a functional scale, the SMAF, and repeated the same comparisons with these severity-matched groups.
RESULTS: The 114 FvAD subjects had a mean age of 78.1 years and Mini-mental State Examination (MMSE) scores of 16.6, and the (remaining) AD group had a mean age of 78.4 years and MMSE of 22.4. There were 30 FTLD subjects with a mean age at baseline of 70.9 years and a mean baseline MMSE of 23.4. The FvAD group was significantly more severely impaired than the other two groups on all baseline assessments except the behavioral scale, the Neuropsychiatric Inventory (NPI), where there was insignificantly less impairment than in the FTLD group. In the analysis of subjects matched at baseline for functional impairment, the FvAD and FTLD groups were not significantly different on most assessment scales although on the FAB, clock-drawing and MMSE the FvAD subjects were still significantly more impaired. These two severity-matched groups were also similar in other baseline characteristics except for older age and less psychotropic use in the FvAD group. The severity-matched FvAD group was significantly different from the AD group in almost all assessment scales. All three unmatched and matched groups declined similarly over 12 months.
CONCLUSIONS: When groups were not matched for baseline severity, the use of the FAB defined a group of AD subjects with greater executive dysfunction that were distinguished from both the remainder of the AD and FTLD subjects in almost all domains except behavioral disturbance and probably were just more severely affected AD subjects. The FAB is thus more useful as a marker of dementia severity than as a scale to detect a frontal variant of AD or to distinguish AD from FTLD. Controlling for severity, however, did allow the definition of a subgroup of AD subjects that more closely resembled FTLD subjects than the remainder of the AD subjects. It is proposed that subjects with dementia presenting with greater executive impairment but without prominent behavioral symptoms are likely to have AD rather than FTLD, especially if they are quite functionally impaired. With time FTLD subjects develop increasing executive dysfunction and increasingly resemble the more severely affected AD subjects.

Entities:  

Mesh:

Year:  2010        PMID: 20719041     DOI: 10.1017/S1041610210001596

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  9 in total

1.  Quantitative and qualitative features of executive dysfunction in frontotemporal and Alzheimer's dementia.

Authors:  Andrew M Kiselica; Jared F Benge
Journal:  Appl Neuropsychol Adult       Date:  2019-08-19       Impact factor: 2.248

Review 2.  New insights into atypical Alzheimer's disease in the era of biomarkers.

Authors:  Jonathan Graff-Radford; Keir X X Yong; Liana G Apostolova; Femke H Bouwman; Maria Carrillo; Bradford C Dickerson; Gil D Rabinovici; Jonathan M Schott; David T Jones; Melissa E Murray
Journal:  Lancet Neurol       Date:  2021-03       Impact factor: 44.182

3.  Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.

Authors:  Artur M N Coutinho; Fábio H G Porto; Fabio L S Duran; Silvana Prando; Carla R Ono; Esther A A F Feitosa; Lívia Spíndola; Maira O de Oliveira; Patrícia H F do Vale; Helio R Gomes; Ricardo Nitrini; Sonia M D Brucki; Carlos A Buchpiguel
Journal:  Alzheimers Res Ther       Date:  2015-09-15       Impact factor: 6.982

4.  Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians.

Authors:  Pedro Rosa-Neto; Ging-Yuek Hsiung; Mario Masellis
Journal:  Alzheimers Res Ther       Date:  2013-11-25       Impact factor: 6.982

Review 5.  Cerebral correlates of psychotic syndromes in neurodegenerative diseases.

Authors:  Kurt A Jellinger
Journal:  J Cell Mol Med       Date:  2012-05       Impact factor: 5.310

6.  Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.

Authors:  Christian Puzo; Caroline Labriola; Michael A Sugarman; Yorghos Tripodis; Brett Martin; Joseph N Palmisano; Eric G Steinberg; Thor D Stein; Neil W Kowall; Ann C McKee; Jesse Mez; Ronald J Killiany; Robert A Stern; Michael L Alosco
Journal:  Alzheimers Res Ther       Date:  2019-07-27       Impact factor: 6.982

Review 7.  Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome.

Authors:  Benjamin Lam; Mario Masellis; Morris Freedman; Donald T Stuss; Sandra E Black
Journal:  Alzheimers Res Ther       Date:  2013-01-09       Impact factor: 6.982

8.  An Initial Empirical Operationalization of the Earliest Stages of the Alzheimer's Continuum.

Authors:  Andrew M Kiselica; Alyssa N Kaser; Jared F Benge
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Jan-Mar 01       Impact factor: 2.357

9.  Measuring executive dysfunction in Parkinson's disease: Reliability and validity of the Spanish version of Frontal Assessment Battery (FAB-E).

Authors:  Miriam Hurtado-Pomares; María Carmen Terol-Cantero; Alicia Sánchez-Pérez; Carlos Leiva-Santana; Paula Peral-Gómez; Desirée Valera-Gran; Eva María Navarrete-Muñoz
Journal:  PLoS One       Date:  2018-11-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.